JPMorgan Chase & Co. cut its holdings in shares of Proteostasis Therapeutics, Inc. (NASDAQ:PTI) by 43.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 214,052 shares of the company’s stock after selling 164,316 shares during the period. JPMorgan Chase & Co. owned about 0.85% of Proteostasis Therapeutics worth $1,001,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Teachers Advisors LLC grew its stake in shares of Proteostasis Therapeutics by 21.4% during the fourth quarter. Teachers Advisors LLC now owns 12,617 shares of the company’s stock valued at $155,000 after acquiring an additional 2,223 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Proteostasis Therapeutics during the first quarter valued at about $100,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Proteostasis Therapeutics during the first quarter valued at about $112,000. Oxford Asset Management acquired a new stake in shares of Proteostasis Therapeutics during the first quarter valued at about $185,000. Finally, LMR Partners LLP acquired a new stake in shares of Proteostasis Therapeutics during the second quarter valued at about $127,000. Institutional investors own 73.71% of the company’s stock.

Proteostasis Therapeutics, Inc. (PTI) opened at 2.10 on Friday. The stock’s 50 day moving average is $2.08 and its 200 day moving average is $3.73. The company’s market cap is $52.71 million. Proteostasis Therapeutics, Inc. has a 12 month low of $1.71 and a 12 month high of $16.67.

Several analysts have recently weighed in on PTI shares. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Proteostasis Therapeutics in a research note on Friday, June 30th. Zacks Investment Research raised shares of Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $9.00 price target (down previously from $17.00) on shares of Proteostasis Therapeutics in a research report on Wednesday, August 16th.

ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/20/proteostasis-therapeutics-inc-pti-stake-decreased-by-jpmorgan-chase-co.html.

Proteostasis Therapeutics Profile

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Want to see what other hedge funds are holding PTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Proteostasis Therapeutics, Inc. (NASDAQ:PTI).

Institutional Ownership by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Stock Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related stocks with our FREE daily email newsletter.